Adverse drug reactions (ADR) are of major concern in drug development. A common form of ADR is liver toxicity, caused by the metabolism of drugs in hepatocytes.

Drugs (or their metabolites) may trigger apoptosis or necrosis of hepatocytes. Different toxic stimuli are expected to be associated with different cell death modes.

Keratin 18 (K18) biomarkers can be used to determine cell death modes in plasma samples. Caspase-cleaved K18 reflects apoptotic cell death, whereas total K18 is a measure of total cell death (necrosis and apoptosis). Apoptosis can be measured using the M30 Apoptosense® ELISA and the M65 EpiDeath® ELISA quantifies total cell death.

The M30 Apoptosense® ELISA has been extensively used to show that serum/plasma levels of caspase-cleaved K18 are elevated in patients with liver injuries. A major advantage of this approach is that the analyte measured by the M30 Apoptosense® ELISA is an end product of the apoptotic process reflecting the extent of active disease (ongoing apoptosis).

K18 is a cytoskeletal protein which is abundantly expressed in hepatocytes. The liver is a large organ and hepatocytes are in direct contact with blood. Therefore, plasma K18 is likely to be derived from liver tissue in patients with no other diseases (such as large tumours or renal failure).
Apoptosis is a regulated form of cell death. Intracellular proteins including keratin 18 are degraded by a class of proteases called caspases. K18 is cleaved at amino acid Asp396.

Necrosis is an uncontrolled form of cell death characterized by disintegration of the membrane and leakage of cell content into the extracellular compartment.

During late phases of apoptosis, intracellular protein fragments may be released into the extracellular compartment and into the blood stream.

Both the cleaved and uncleaved forms of K18 are relatively stable in blood. The levels of total K18 reflect total cell death due to either necrosis or apoptosis, whereas the levels of caspase-cleaved K18 reflect apoptosis.

The different molecular forms of K18 can be determined by specific ELISA assays. The M30 Apoptosense® ELISA utilizes the M30 monoclonal antibody, which is specific for the Asp396 neo-epitope and does not bind to the native protein. Therefore, the M30 Apoptosense ELISA is specific for apoptosis.

The M65 EpiDeath® ELISA measures total cell death (necrosis and apoptosis).

The combination of the M30 Apoptosense® ELISA and the M65 EpiDeath® ELISA allows both quantitative and qualitative determination of cell death.
**APAP hepatoxicity correlates with K18 levels**

Antoine et al., 2009 studied the use of K18 as a serum biomarker for drug induced liver injury. The concentrations of caspase-cleaved and native K18 were significantly increased after induction of acetaminophen (APAP) induced liver toxicity. The values correlated strongly with histological changes and in situ cell loss and the time-course of injury.

Interestingly, the ratio between caspase-cleaved and full-length K18 indicated a change of cell death mode over time from an apoptotic onset to cell death dominated by necrosis in later stages.

Increases of K18 serum levels correlated well with ALT levels, but were observed at earlier timepoints. Generally, K18 was reported to be a sensitive and specific indicator of hepatotoxicity.

**Reference**


**Toxicant induced liver injury**

Vinyl chloride (VC) is a potent liver toxic chemical widely used in the industry. VC workers exposed to VC on a regular basis may develop liver steatosis and fibrosis.

Liver injuries in VC workers, verified by liver biopsies, were reported to correlate with K18 blood concentrations, despite normal ALT values (Cave et al., 2010). An influence of obesity or alcohol abuse could be ruled out, leaving the toxic effect of VC as the only reasonable cause for the liver diseases.

Both forms of K18 were analyzed and necrosis was found to be the mechanism of cell death. Monitoring serum K18 levels should be useful for identification of individuals that are being exposed to harmful amounts of toxic chemicals.

**Reference**


**K18 levels are elevated in ALF and NASH**

Apoptosis is the major mechanism leading to fibrosis in liver diseases such as alcoholic (ASH) or non-alcoholic (NASH) steatohepatitis and hepatitis B or C virus infection. As a result, caspase-cleaved K18 concentrations are significantly elevated in patients with these diseases.

In blood samples from patients with acute liver failure (ALF), the concentrations of both forms of K18 are highly elevated. It has been reported that the distinction between apoptosis and necrosis may be useful for predicting the outcome of ALF.

**References**

Volkmann et al., Caspase activation is associated with spontaneous recovery from acute liver failure. *Hepatology.* 2008 47: 1624–33.
M30 Apoptosense® ELISA

- Specific measurement of apoptosis in epithelial cells (hepatocytes)
- Samples: Human serum or plasma, or cell culture supernatants or cell lysates from human cell lines; no sample preparation required
- Sample stability: at least 1 day at 2 – 8 °C, at least 9 months at -20 °C, at least 2 years at -80 °C; freeze-thawing is well tolerated
- Sandwich ELISA with precoated microplate, 12 × 8 wells; kit includes all necessary reagents
- Registered in accordance with the CE directive; manufactured according to ISO 9001 and ISO 13485 guidelines

M65 EpiDeath® ELISA

- Specific measurement of total cell death in epithelial cells (hepatocytes)
- Samples: Human serum or plasma, or cell culture supernatants from human cell lines; no sample preparation required
- Sample stability: at least 1 day at 2 – 8 °C, at least 9 months at -20 °C, at least 2 years at -80 °C; freeze-thawing is well tolerated
- Sandwich ELISA with precoated microplate, 12 × 8 wells; kit includes all necessary reagents
- Registered in accordance with the CE directive; manufactured according to ISO 9001 and ISO 13485 guidelines

Products from PEVIVA

<table>
<thead>
<tr>
<th>Product</th>
<th>Prod. no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>M30 Apoptosense® ELISA</td>
<td>10010</td>
</tr>
<tr>
<td>M65® ELISA</td>
<td>10020</td>
</tr>
<tr>
<td>M65 EpiDeath® ELISA</td>
<td>10040</td>
</tr>
<tr>
<td>M30 CytoDeath™ ELISA</td>
<td>10900</td>
</tr>
<tr>
<td>M30 Apoptosense® ELISA</td>
<td>10010</td>
</tr>
<tr>
<td>M6 Keratin™ 18 mAb</td>
<td>10600</td>
</tr>
<tr>
<td>M6 Keratin™ 18 mAb</td>
<td>10650</td>
</tr>
<tr>
<td>M30 CytoDEATH™ mAb</td>
<td>10700</td>
</tr>
<tr>
<td>Unconjugated:</td>
<td>Prod. no 10700</td>
</tr>
<tr>
<td>Biotin:</td>
<td>Prod. no 10750</td>
</tr>
<tr>
<td>Fluorescein:</td>
<td>Prod. no 10800</td>
</tr>
<tr>
<td>Orange:</td>
<td>Prod. no 10830</td>
</tr>
<tr>
<td>Red:</td>
<td>Prod. no 10850</td>
</tr>
</tbody>
</table>

Contact

Order and inquiries
- order@peviva.net
- +46-8-122 053 00
- +46-8-730 16 10

Technical support
- support@peviva.net
- +46-8-122 053 08
- +46-8-730 16 10

PEVIVA AB, Voltavägen 13, 168 69 Bromma, Sweden
Website: www.peviva.se • E-mail: info@peviva.se
Phone: +46 (0)8 122 053 00 • Fax: +46 (0)8 730 16 10